RTI Surgical, Inc. (RTIX) Analysts See $0.03 EPS

February 14, 2018 - By Marie Mckinney

 RTI Surgical, Inc. (RTIX) Analysts See $0.03 EPS
Investors sentiment decreased to 1.11 in Q3 2017. Its down 0.56, from 1.67 in 2017Q2. It is negative, as 9 investors sold RTI Surgical, Inc. shares while 29 reduced holdings. 14 funds opened positions while 28 raised stakes. 41.65 million shares or 1.69% more from 40.96 million shares in 2017Q2 were reported.
Gabelli Funds Lc accumulated 200,000 shares or 0.01% of the stock. Bnp Paribas Arbitrage Sa owns 6,132 shares. Matarin Capital Management Limited Liability Co stated it has 0.01% in RTI Surgical, Inc. (NASDAQ:RTIX). Millennium Management Limited Liability Corporation invested in 293,139 shares or 0% of the stock. Manufacturers Life Insurance The reported 45,871 shares or 0% of all its holdings. Moreover, Menta Capital Limited Liability has 0.1% invested in RTI Surgical, Inc. (NASDAQ:RTIX). Krensavage Asset Mgmt has invested 6.26% in RTI Surgical, Inc. (NASDAQ:RTIX). Mackenzie Fincl, Ontario – Canada-based fund reported 10,272 shares. Citadel Advsr Llc reported 26,786 shares. Prelude Cap Mngmt Ltd Liability Corporation owns 3,500 shares. Deutsche Natl Bank Ag has invested 0% in RTI Surgical, Inc. (NASDAQ:RTIX). Credit Suisse Ag reported 39,960 shares or 0% of all its holdings. California Pub Employees Retirement Systems has invested 0% in RTI Surgical, Inc. (NASDAQ:RTIX). Tiaa Cref Inv Lc, a New York-based fund reported 176,530 shares. Parametric Port Associates Lc holds 0% or 28,757 shares in its portfolio.

Analysts expect RTI Surgical, Inc. (NASDAQ:RTIX) to report $0.03 EPS on February, 22.They anticipate $0.02 EPS change or 200.00 % from last quarter’s $0.01 EPS. RTIX’s profit would be $1.82M giving it 37.50 P/E if the $0.03 EPS is correct. After having $0.01 EPS previously, RTI Surgical, Inc.’s analysts see 200.00 % EPS growth. The stock increased 2.27% or $0.1 during the last trading session, reaching $4.5. About 93,761 shares traded. RTI Surgical, Inc. (NASDAQ:RTIX) has risen 30.73% since February 14, 2017 and is uptrending. It has outperformed by 14.03% the S&P500.

RTI Surgical, Inc., together with its subsidiaries, designs, develops, makes, and distributes orthopedic and other surgical implants for use in various surgical procedures worldwide. The company has market cap of $273.75 million. The firm provides natural tissue implants, as well as metal and synthetic implants for the treatment of spinal and other orthopedic disorders. It currently has negative earnings. It processes donated human musculoskeletal and other tissues, including bone, cartilage, tendons, ligaments, fascia lata, pericardium, sclera, cornea, and dermal tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes.

More notable recent RTI Surgical, Inc. (NASDAQ:RTIX) news were published by: Businesswire.com which released: “Continues to Augment Leadership Team to Accelerate its Strategic Direction” on September 18, 2017, also Nasdaq.com with their article: “RTI Surgical (RTIX) to Acquire Zyga, Improve Spine Surgeries” published on January 08, 2018, Businesswire.com published: “RTI Surgical Outlines 2018 Guidance and Long-Term Goals” on January 05, 2018. More interesting news about RTI Surgical, Inc. (NASDAQ:RTIX) were released by: Reuters.com and their article: “BRIEF-RTI Surgical divests cardiothoracic closure business to A&E Medical Corp” published on August 03, 2017 as well as Businesswire.com‘s news article titled: “Divests Cardiothoracic Closure Business to A&E Medical Corporation for up to …” with publication date: August 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: